ANTI-MÜLLERIAN HORMONE AND INHIBIN-B LEVEL PROFILE IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL AND CISPLATIN COMBINATION

  • Nusratuddin Abdullah Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
  • Anggrainy Dwifitriana Kouwagam Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
  • A. Andina Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia

Abstract

Background: The age of nulliparous women has increased in developed countries and the 5-year survival rate for the late stage does not exceed 58%. Moreover, as more women are delaying childbearing, preservation of fertility and reproductive function is a major concern when young women are counseled with regard to the effects of treatment for cervical cancer. Objective: To determine the effect of the combination chemotherapy on serum levels of Anti-Mullerian Hormone (AMH) and inhibin B. Methods: This study is a prospective cohort study in 16 cervical cancer patients aged 28-48 years who received Paclitaxel-Cisplatin chemotherapy. AMH and inhibin B levels were examined before and after third series chemotherapy. Statistical analysis used the Wilcoxon test with a level of significance selected at 0.05. Results: There is a significant decrease in median serum levels of AMH and inhibin B patients between before and after Paclitaxel–Cisplatin chemotherapy with p=0.000 (P<0.05). Similarly, a decrease in the median value of serum levels of AMH and inihibin B after Paclitaxel-Cisplatin chemotherapy in each series of chemotherapy was significant with p=0.000 (P<0.05). Conclusions: Serum levels of AMH and inhibin B in cervical cancer patients who received the combination chemotherapy decreased dramatically after 3 months of chemotherapy and the factors that contribute to the diminution is age.

Downloads

Download data is not yet available.

Author Biographies

Nusratuddin Abdullah, Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
Anggrainy Dwifitriana Kouwagam, Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
A. Andina, Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
Published
2014-06-04
How to Cite
ABDULLAH, Nusratuddin; KOUWAGAM, Anggrainy Dwifitriana; ANDINA, A.. ANTI-MÜLLERIAN HORMONE AND INHIBIN-B LEVEL PROFILE IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL AND CISPLATIN COMBINATION. BALI MEDICAL JOURNAL, [S.l.], v. 3, n. 2, june 2014. ISSN 2302-2914. Available at: <https://ojs.unud.ac.id/index.php/bmj/article/view/21592>. Date accessed: 13 nov. 2024.
Section
Articles

Keywords

Chemotherapy, Ovarian reserve, AMH, Inhibin B